Products
Empasiprubart Biosimilar Monoclonal Antibody (Complement C2) for Research
Cat No.: GMP-Bios-INN-1179
Anti-C2 therapeutic antibody (Pre-made Empasiprubart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Empasiprubart (development code ARGX-117) is a monoclonal antibody targeting complement C2 (C2). It is developed by arGEN-X and Broteio for multifocal motor neuropathy, dermatomyositis, kidney disorders among others. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1179-1mg | 1mg | 3090 |
| GMP-Bios-INN-1179-10mg | 10mg | |
| GMP-Bios-INN-1179-100mg | 100mg | |
| GMP-Bios-INN-1179-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Empasiprubart biosimilar, Whole mAb, Anti-C2 Antibody: Anti-C2/Complement C2/C3/C5 convertase therapeutic antibody |
| INN Name | Empasiprubart |
| Target | C2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | 8acf:HL/8aci:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | arGEN-X;Broteio |
| Conditions Approved | na |
| Conditions Active | Multifocal motor neuropathy;Dermatomyositis;Kidney disorders;Motor neuron disease |
| Conditions Discontinued | COVID-19 |
| Production | na |
| Development Tech | na |
